Zhang MY, Zhao Y, Liu JF, Liu GP, Zhang RY, Wang LM. Efficacy of different antibiotics in treatment of children with respiratory mycoplasma infection. World J Clin Cases 2021; 9(23): 6717-6724 [PMID: 34447818 DOI: 10.12998/wjcc.v9.i23.6717]
Corresponding Author of This Article
Li-Min Wang, PhD, Staff Physician, Department of Pediatrics, Qingdao Municipal Hospital, No. 1 Jiaozhou Road, Shibei District, Qingdao 266011, Shandong Province, China. wanglimin1020@126.com
Research Domain of This Article
Respiratory System
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Aug 16, 2021; 9(23): 6717-6724 Published online Aug 16, 2021. doi: 10.12998/wjcc.v9.i23.6717
Efficacy of different antibiotics in treatment of children with respiratory mycoplasma infection
Mei-Ying Zhang, Yan Zhao, Jin-Feng Liu, Guo-Ping Liu, Rui-Yun Zhang, Li-Min Wang
Mei-Ying Zhang, Yan Zhao, Rui-Yun Zhang, Li-Min Wang, Department of Pediatrics, Qingdao Municipal Hospital, Qingdao 266011, Shandong Province, China
Jin-Feng Liu, Department of ICU, Jinan City People’s Hospital, Jinan 271199, Shandong Province, China
Guo-Ping Liu, Department of Interventional Radiology, Affiliated Hospital of Qingdao University, Qingdao 266003, Shandong Province, China
Author contributions: Zhang MY and Zhao Y designed the study; Liu JF drafted the work; Liu GP and Zhang RY collected the data; Zhang MY analyzed and interpreted the data; Zhang MY, Zhao Y, and Wang LM wrote the article.
Institutional review board statement: The study was reviewed and approved by the Qingdao Municipal Hospital Institutional Review Board.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: The authors declare that there is no conflict of interest to disclose.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Li-Min Wang, PhD, Staff Physician, Department of Pediatrics, Qingdao Municipal Hospital, No. 1 Jiaozhou Road, Shibei District, Qingdao 266011, Shandong Province, China. wanglimin1020@126.com
Received: March 2, 2021 Peer-review started: March 2, 2021 First decision: April 4, 2021 Revised: April 6, 2021 Accepted: May 15, 2021 Article in press: May 15, 2021 Published online: August 16, 2021
ARTICLE HIGHLIGHTS
Research background
Children are more susceptible to infection with Mycoplasma pneumoniae. At the same time, they are more susceptible to disease after infection and have difficulty breathing and can experience respiratory failure or critical illness. The treatment of this disease has received widespread clinical attention.
Research motivation
To search drugs that can replace erythromycin in the treatment of respiratory tract infections in children.
Research objectives
This study aimed to analyze the clinical efficacy of different antibiotics in the treatment of pediatric respiratory mycoplasma infection.
Research methods
One hundred and six children diagnosed with respiratory mycoplasma infection were included in this study. The clinical efficacy was evaluated and compared between groups. The compliance of children during treatment was evaluated and compared between groups.
Research results
The total effective rate of clinical treatment of children in the clarithromycin group was significantly higher than that in the erythromycin group. The incidence of toxic and side effects in the clarithromycin group was significantly lower than that in the erythromycin group, and the above data comparisons were statistically significant.
Research conclusions
Clarithromycin has a variety of advantages over erythromycin, such as higher application safety, stronger mycoplasma clearance, and higher medication compliance in children, and can be actively promoted.
Research perspectives
Clarithromycin is superior to erythromycin in terms of application effect, safety, and economic benefits and can be preferentially selected.
